Leidos to Help USAID Facilitate Malaria Vaccine R&D Projects; Jerry Hogge Comments

LeidosLogoLeidos (NYSE: LDOS) has been awarded a potential five-year, $23.7 million contract to support the U.S. Agency for International Development‘s efforts to research and develop a vaccine against malaria.

The company said Monday it will provide scientific and management services for USAID’s Malaria Vaccine Development Program under the cost-plus-fixed-fee contract.

Jerry Hogge, Leidos health deputy group president, said the company brings decades of life sciences technology and experience to the USAID program.

Leidos said the work to occur in Frederick, Maryland, could also evaluate malaria vaccine candidates during preclinical studies and clinical and field trials.

The company’s life sciences team supports medical product R&D efforts at the National Institutes of Health and the departments of Defense and Homeland Security.

You may also be interested in...

DISA

DISA Seeks Potential FAMIS-WCF Financial System Sustainment, Enhancement Support Sources

The Defense Information Systems Agency has started to seek information on potential vendors that could help enhance and provide sustainment support for DISA’s Financial Accounting Management Information System for the Working Capital Funds platform.

Potomac Officers Club Hosts PNT Superiority on the Future Battlefield

Potomac Officers Club’s Ensuring PNT Superiority on the Future Battlefield Hosted Expert Panel to Discuss Defense Resilience and Capabilities

During Potomac Officers Club’s Ensuring PNT Superiority on the Future Battlefield Virtual Event, an expert panel, comprised of notable leaders across the defense sector, took the stage to discuss how military PNT capabilities have become vital to the nation’s ability to shape the global environment, deter aggression, and fight and win wars, now and in the future.